Filing Details
- Accession Number:
- 0001104659-25-043648
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-05-01 20:59:30
- Reporting Period:
- 2025-03-19
- Filing Date:
- 2025-05-01
- Accepted Time:
- 2025-05-01 20:59:30
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1657312 | Verona Pharma Plc | VRNA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 2014301 | Andrew Fisher | 3 More London Riverside London X0 SE1 2RE | General Counsel | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2025-03-19 | 1 | $0.00 | 300,001 | No | 4 | G | Direct | |
| Ordinary Shares | Acquisiton | 2025-04-29 | 86,064 | $0.00 | 386,065 | No | 4 | M | Direct | |
| Ordinary Shares | Disposition | 2025-04-29 | 26,072 | $8.98 | 359,993 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | G | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Restricted Share Units | Acquisiton | 2025-04-29 | 253,120 | $0.00 | 253,120 | $0.00 |
| Ordinary Shares | Restricted Share Units | Disposition | 2025-04-29 | 86,064 | $0.00 | 86,064 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 253,120 | No | 4 | A | Direct | ||
| 167,056 | No | 4 | M | Direct |
Footnotes
- Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
- The sale reported in this Form 4 was effected solely with the intent to cover taxes in connection with the vesting of Restricted Share Units.
- The price reported represents the sale price of the ADSs divided by eight (8).
- Consists of (i) 300,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 37,500 ADSs), (ii) 59,992 Ordinary Shares underlying 7,499 ADSs, and (iii) 1 Ordinary Share.
- Represents an award of performance-based Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"), which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.
- The RSUs were earned upon the determination by the Board of Directors of the Issuer (the "Determination Date") that certain performance metrics related to Q1 2025 had been achieved. The RSUs vested as to 34% of the total shares on the Determination Date, and vest as to the remainder of the shares in equal quarterly installments over a two year period on each of August 1, November 1, February 1 and May 1, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Billionaire Hedge Funds
